Grant of options

RNS Number : 0390C

N4 Pharma PLC

26 September 2018

 

26 September 2018

N4 Pharma Plc

("N4 Pharma" or the "Company")

Grant of options

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company, announces that the Company has today granted a total of 1,004,000 options over ordinary shares in the Company ("Ordinary Shares") to certain members of senior management pursuant to the Company's unapproved share options scheme (the "Options"). The Options have been granted as follows:

Name	Options over Ordinary Shares previously held	Number of Options granted	Total number of options over Ordinary Shares now held
Allen Hey, Head of CMC Program Development, Biologics	0	717,143	717,143
Andrew Leishman, Head of Nuvec Development	0	286,857	286,857

The Options have an exercise price of 6.60p, which was the closing mid-market price of an Ordinary Share in the Company on 25 September 2018, being the day prior to the grant, and can be exercised from three years up until ten years from the date of grant.  Following this grant of Options, there are a total of 7,249,084 options outstanding over Ordinary Shares and 11,054,071 warrants outstanding over Ordinary Shares.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Allen William Hey
2	Reason for the notification
a)	Position/status	Head of CMC Program Development, Biologics, a PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	N4 Pharma plc
b)	LEI	213800OIN8T68PM7HK77
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.4p each in N4 Pharma PLC Identification code (ISIN) for N4 Pharma PLC ordinary shares: GB00BYW8QM32
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)	Price(s) Volume(s) Exercise price of 6.6p 717,143
d)	Aggregated information - Aggregated volume - Price	n/a
e)	Date of the transaction	26 September 2018
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Andrew Leishman
2	Reason for the notification
a)	Position/status	Head of Nuvec Development, a PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	N4 Pharma plc
b)	LEI	213800OIN8T68PM7HK77
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.4p each in N4 Pharma PLC Identification code (ISIN) for N4 Pharma PLC ordinary shares: GB00BYW8QM32
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)	Price(s) Volume(s) Exercise price of 6.6p 286,857
d)	Aggregated information - Aggregated volume - Price	n/a
e)	Date of the transaction	26 September 2018
f)	Place of the transaction	Outside a trading venue

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO	Via Alma PR
Allenby Capital Limited James Reeve/Virginia Bull/Asha Chotai	Tel: [phone]
Alma PR Josh Royston Robyn Fisher	Tel: [phone] Tel: [phone]

 

END

 

 

DSHLFMTTMBITBFP